Wells Fargo’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $316K | Buy |
+67,712
| New | +$278K | ﹤0.01% | 4911 |
|
|
2025
Q3 | – | Sell |
-348
| Closed | -$661 | – | 7434 |
|
|
2025
Q2 | $661 | Sell |
348
-2,370
| -87% | -$9.7K | ﹤0.01% | 6351 |
|
|
2025
Q1 | $19.3K | Buy |
2,718
+101
| +4% | +$1.39K | ﹤0.01% | 5724 |
|
|
2024
Q4 | $57.6K | Buy |
2,617
+892
| +52% | +$14.2K | ﹤0.01% | 5432 |
|
|
2024
Q3 | $34.6K | Sell |
1,725
-68
| -4% | -$1.42K | ﹤0.01% | 5480 |
|
|
2024
Q2 | $31.2K | Buy |
1,793
+428
| +31% | +$14K | ﹤0.01% | 5452 |
|
|
2024
Q1 | $56.9K | Buy |
1,365
+198
| +17% | +$5.51K | ﹤0.01% | 5205 |
|
|
2023
Q4 | $29.4K | Buy |
1,167
+246
| +27% | +$5.98K | ﹤0.01% | 5485 |
|
|
2023
Q3 | $30.1K | Sell |
921
-714
| -44% | -$31.1K | ﹤0.01% | 5431 |
|
|
2023
Q2 | $95.2K | Buy |
1,635
+1,610
| +6,440% | +$82.7K | ﹤0.01% | 5071 |
|
|
2023
Q1 | $655 | Buy |
25
+11
| +79% | +$323 | ﹤0.01% | 6486 |
|
|
2022
Q4 | $424 | Sell |
14
-5
| -26% | -$237 | ﹤0.01% | 6429 |
|
|
2022
Q3 | $1K | Buy |
19
+13
| +217% | +$449 | ﹤0.01% | 6485 |
|
|
2022
Q2 | $0 | Buy |
6
+1
| +20% | +$38 | ﹤0.01% | 7608 |
|
|
2022
Q1 | $0 | Buy |
5
+1
| +25% | +$57 | ﹤0.01% | 7935 |
|
|
2021
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 7900 |
|
|
2021
Q3 | $1K | Hold |
4
| – | – | ﹤0.01% | 6814 |
|
|
2021
Q2 | $1K | Sell |
4
-182
| -98% | -$45.8K | ﹤0.01% | 6756 |
|
|
2021
Q1 | $48K | Sell |
186
-719
| -79% | -$189K | ﹤0.01% | 5829 |
|
|
2020
Q4 | $174K | Buy |
905
+464
| +105% | +$91.1K | ﹤0.01% | 5139 |
|
|
2020
Q3 | $89K | Sell |
441
-140
| -24% | -$33.6K | ﹤0.01% | 5310 |
|
|
2020
Q2 | $163K | Sell |
581
-224
| -28% | -$61.3K | ﹤0.01% | 5015 |
|
|
2020
Q1 | $242K | Buy |
805
+21
| +3% | +$5.96K | ﹤0.01% | 4563 |
|
|
2019
Q4 | $252K | Buy |
784
+19
| +2% | +$6.81K | ﹤0.01% | 4822 |
|
|
2019
Q3 | $292K | Buy |
765
+387
| +102% | +$153K | ﹤0.01% | 4737 |
|
|
2019
Q2 | $170K | Buy |
378
+363
| +2,420% | +$185K | ﹤0.01% | 5061 |
|
|
2019
Q1 | $8K | Hold |
15
| – | – | ﹤0.01% | 5675 |
|
|
2018
Q4 | $6K | Hold |
15
| – | – | ﹤0.01% | 6056 |
|
|
2018
Q3 | $4K | Buy |
15
+1
| +7% | +$424 | ﹤0.01% | 6154 |
|
|
2018
Q2 | $9K | Sell |
14
-1
| -7% | -$3.27K | ﹤0.01% | 5983 |
|
|
2018
Q1 | $60K | Buy |
+15
| New | +$43.6K | ﹤0.01% | 5505 |
|
Other funds holding XFOR
BCLSI
PA
SVCM
EAM
DTC
KCM
Wells Fargo's XFOR Position: Q2 2026 in Review
Wells Fargo opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 67,712 shares worth $316K. The stake represents ﹤0.01% of the portfolio and ranks #4911 among its holdings. This is a return to the name: Wells Fargo previously reported a position in XFOR as recently as Q2 2025.
Wells Fargo first reported a position in XFOR in Q1 2018 and has held it in 31 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- Wells Fargo held 67,712 shares of X4 Pharmaceuticals worth $316K as of Q2 2026.
- X4 Pharmaceuticals was a new Wells Fargo position in Q2 2026.
- X4 Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4911 holding.
- Wells Fargo first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
- 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.